Promoter holding
64.27%
CP
Caplin Point Laboratories Limited - Due diligence report
A 360° intelligence report on Caplin Point Laboratories: trust score, financial health, credit view, compliance, directors, growth and distr…
Full Due-Diligence Report + Documents
- Unlock all financial figures & 5-year trends
- Full trust, health & credit-risk scores
- Director details, charges & MCA documents
₹700
₹349
50% off
New user
Or enjoy up to 50% off with credits
View credit packages
Company Credits – Starter
- One credit unlocks this full due-diligence report
- Use across any company’s report, anytime
- Credits valid for 12 months
Choose your own credit amount
View credit packages
Caplin Point Laboratories — 360° Intelligence Report
Generated from MCA filings & public records79/100
Trust Score
Low Risk
Caplin Point Laboratories is assessed as Low Risk with a Trust Score of 79/100. Caplin Point Laboratories is an active public limited indian non-government company incorporated in 1990, operating in the Pharma sector. The company has shown revenue growth across its recent filed years. It was profitable in its latest filed year. Based on MCA filings and public records, it currently shows a moderate compliance risk and low financial risk profile.
Report generated on 07 Jul 2026 from the latest processed filings. Caplin Point Laboratories Limited snapshot & full profile →
Automated indicators derived from public MCA / GST / EPFO records - not a credit rating, not investment, legal or financial advice. Spotted an inaccuracy? Report an error.
02
Score Card
Higher is safer · rule-based & explainableTrust ScoreLow Risk
79/100
Overall counterparty trust - the headline number of this report.
Compliance ScoreModerate
50/100
Statutory standing - status, filings, auditor, MSME and litigation.
Financial Health ScoreLow Risk
90/100
Profitability, leverage and liquidity from filed statements.
Credit Risk ScoreLow Risk
85/100
Debt capacity, gearing and security cover for lenders.
Director Stability ScoreLow Risk
95/100
Board strength, DIN status, churn and network.
Growth ScoreLow Risk
95/100
Revenue, profit, asset and hiring momentum.
Distress ScoreLow Risk
80/100
Early-warning signals - higher means fewer warnings.
03
Financial Intelligence Dashboard
Consolidated · 5 filed year(s)Unlock the full 5-year financial dashboard with charts and year-wise figures.
Get full accessScores and observations on this page are already computed from the real filings - only the underlying figures are locked.
04
Credit & Compliance Intelligence
Why the scores are what they are
Credit Risk Score: 85/100 Low Risk
- Liabilities ≈ 38% EBITDA - serviceable.
- Working-capital cover adequate.
- Profitable - internal accruals available.
Charges position: 1 open (10.00 Lakh) · 17 satisfied (102.92 cr).
Banking relationships (from registered charges)
| Lender | Charges | Amount |
|---|---|---|
| The Catholic Syrian Bank Ltd | 2 | 48.0 cr |
| Others | 4 | 48.0 cr |
| The Catholic Syrian Bank Limited | 2 | 48.0 cr |
| Bank Of India | 6 | 48.0 cr |
| Karnataka Bank Ltd. | 1 | 48.0 cr |
| Catholic Syrian Limited | 1 | 48.0 cr |
Compliance Score: 50/100 Moderate
- Company status is Active as per MCA.
- Annual filings current (balance sheet Mar 2025).
- Flagged by authority: NSDL, BSE, CDSL.
- Litigation present in 3 court forum(s).
- 4 active GST registration(s).
Legal cases on record (3)
05
Director Intelligence
Stability score: 95/100| Name | DIN / PAN | Designation | Appointed | Tenure | DIN status |
|---|---|---|---|---|---|
| KOMATTU CHACKO JOHN | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| DESIKACHARI MURALIDHARAN | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| RAMACHANDRAMURTHY NAGENDRAN | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| SRIDHAR GANESAN | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| PARTHEEBAN VIVEK SIDDARTH | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| DESIKACHARI MURALIDHARAN | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| RANGANATHAN VIJAYARAGHAVAN | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| ASHOK GORKEY PARTHEEBAN | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| VENKATRAM GANAPATHY SUBRAMANIAN | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| GARIYALI CHANDERKANTA | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| PAARTHIPAN CHINGELPUT CHELLAPPAN | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| DEENADAYALAN SINGARAM | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| Venkatram Ganapathisubramanian | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
- 13 directors on the board.
- No disqualified or deactivated DINs.
- Stable board - no exits in 3 years.
- Average tenure above 5 years.
Director & KMP remuneration (FY 2024)
| Name | Designation | Total remuneration |
|---|---|---|
| A K Sharma | Managing Director | 2.4 cr |
| R Mehta | Whole-time Director | 1.6 cr |
| S Iyer | CFO | 95.0 L |
Remuneration is disclosed in the latest annual return. Unlock full report
06
Ownership & Group Intelligence
As per FY 2025 annual returnPublic / other holding
35.73%
Equity shares
12,45,67,890
Equity paid-up
124.5 cr
Promoters on record
4
Ultimate holding entity
-
Subsidiaries
4
Group entities
5
Capital events
9 allotment(s) · 0 transfer(s)
Promoters hold a minority stake - exact percentages are part of the full report.
| Group entity | Relationship | % held |
|---|---|---|
| Caplin Steriles Usa Inc. | Subsidiary Company | 74.00% |
| Caplin Point (s) Pte. Ltd. | Subsidiary Company | 74.00% |
| Caplin One Labs Limited | Subsidiary Company | 74.00% |
| Caplin Steriles Limited | Subsidiary Company | 74.00% |
| Sunsole Solar Private Limited | Associate Company | 74.00% |
Key managerial personnel: DESIKACHARI MURALIDHARAN (CFO) · DESIKACHARI MURALIDHARAN (CFO)
Full shareholding pattern, group structure & capital events →
07
Risk Intelligence Center
Growth 95 · Distress 80
Growth signals & trust indicators
Revenue acceleration: +1.42 over 4 year(s).
Latest year revenue grew 2.1x.
Profit expanded 24% year-on-year.
Asset base grew 0.86 - capacity expansion.
Net margin improved to 61%.
EPFO headcount growing - hiring signal.
Operating for 36+ years.
Active EPFO - real payroll on record.
Active GST registration(s).
Distress signals & risk flags
Outside liabilities up 38% in a year.
Compliance score is weak (50/100).
1 open charge(s) registered - assets are encumbered.
3 court case(s) on record - see the legal section for details.
08
Stakeholder Verdicts
Vendor · Banker · InvestorVendor due diligence68/100
Review suggested
Suitability as a supplier / customer counterparty.
- Check the compliance flags before onboarding.
- 1 distress signal(s) - see Risk Center.
- Financial filings available for verification.
Banker assessment78/100
Favourable lending indicators
Indicative lending comfort for banks, NBFCs and trade credit.
- Debt capacity assessed from filed statements.
- 1 open charge(s) of 10.00 Lakh already registered.
- Compliance gaps should be priced into terms.
Investor view89/100
Positive growth indicators
Growth quality and scalability through an investor lens.
- 6 growth signal(s) detected.
- Margin and return trends computable from filings.
- Management team looks stable.
09
MCA Filings & Events Timeline
Latest 15 events05 Nov 2025
Director appointed
KOMATTU CHACKO JOHN (Additional Director)
Director appointed
PARTHEEBAN VIVEK SIDDARTH (Additional Director)
Director appointed
ASHOK GORKEY PARTHEEBAN (Additional Director)
22 Sep 2025
Last AGM held
Annual general meeting
31 Jul 2025
Charge satisfied
The Catholic Syrian Bank Ltd
04 Jun 2025
Charge satisfied
Others
08 May 2025
Charge satisfied
Others
31 Mar 2025
Latest balance sheet
Filed with ROC
30 Sep 2024
Director appointed
RANGANATHAN VIJAYARAGHAVAN (Director)
02 May 2024
Charge created
Others - 7.60 cr
08 Aug 2023
Charge satisfied
Others
28 Apr 2023
Charge created
Others - 10.00 cr
04 Jan 2023
Securities allotted
5500 Equity Shares - 11,000.00 raised
17 Dec 2022
Director ceased
VTHIRUMALAI
15 Dec 2022
Securities allotted
91704 Equity Shares - 1.83 Lakh raised
10
Key Observations
Auto-generated from the data aboveRevenue grew 1.42 over the last 4 financial year(s).
Net profit margin moved from 2.1x to 24%.
Net worth is positive.
13 active director(s) / partner(s); board looks stable and experienced.
4 active GST registration(s) indicate ongoing business operations.
Operates a group structure with 4 subsidiary(ies) - assess on a consolidated basis.
EPFO-registered employer - verifiable payroll history exists.
Promoters hold a minority stake as per the FY 2025 annual return.
Director / KMP remuneration is disclosed in the latest annual return - exact figures available in the full report.
Capital has been raised through 9 security allotment(s) - amounts available in the full report.
17 overseas direct investment(s) (ODI) on record - international footprint.
| Company | CIN | Location |
|---|---|---|
| Shilpa Pharma Lifesciences Limited | U24100KA2020PLC134081 | Raichur, Karnataka, India |
| Jocil | L28990AP1978PLC002260 | Andhra Pradesh, Andhra Pradesh, India |
| Ttk Healthcare | L24231TN1958PLC003647 | Chennai, Tamil Nadu, India |
| Sri Sarvaraya Sugars Limited | L01115TN1956PLC003435 | Chennai, Tamil Nadu, India |
| Camlinfs | L74100MH1993PLC075361 | Mumbai, Maharashtra, India |
| Jayshreetea | L15491WB1945PLC012771 | Kolkata, West Bengal, India |
| Gmm Pfaudler | L29199GJ1962PLC001171 | Karamsad, Gujarat, India |
| Procter & Gamble Health | L99999MH1967PLC013726 | Mumbai, Maharashtra, India |
12
Who Uses This Report
CA · CS · Banker · Investor · VendorChartered Accountants (CA)
Verify Caplin Point Laboratories before audits and certifications: compliance score 50/100, filing history, auditor history and charge records in one place - instead of pulling each MCA form separately.
Company Secretaries (CS)
Track statutory health of Caplin Point Laboratories: ACTIVE compliance status, annual-return recency, director DIN status, board churn and the events timeline - the inputs for secretarial audits and due-diligence certificates.
Bankers & NBFCs
Current banker verdict: Favourable lending indicators. Credit risk score 85/100, existing charge position and lender relationships - a first-pass credit memo before formal appraisal.
Investors & Analysts
Investor view: Positive growth indicators. Growth score 95/100, margin trends, ownership structure and peer set for Caplin Point Laboratories - screening before a deeper diligence.
Vendors & Procurement Teams
Vendor verdict: Review suggested. Trust score 79/100, distress signals and MSME payment-delay disclosures - know whether Caplin Point Laboratories pays its suppliers before you extend credit terms.
Lawyers & Compliance Teams
Litigation footprint (3 case(s) on record), regulatory flags, charge documents trail and director networks for Caplin Point Laboratories - groundwork for KYC, onboarding and disputes.
13
Frequently Asked Questions
Is Caplin Point Laboratories an active company?
Caplin Point Laboratories has MCA status “Active” with a compliance score of 50/100 (Moderate).
Is Caplin Point Laboratories financially healthy?
Caplin Point Laboratories has a Financial Health Score of 90/100 (Low Risk) based on its filed financial statements.
Should I do business with Caplin Point Laboratories?
Its overall Trust Score is 79/100 (Low Risk). Vendor verdict: Review suggested. Review the risk flags in the Risk Intelligence Center before deciding.
Who controls Caplin Point Laboratories?
Promoters hold a minority stake - exact percentages are in the full report. 13 active director(s) are on record.
Does Caplin Point Laboratories have loans or charges against its assets?
1 open charge(s) are registered against its assets, and 17 earlier charge(s) stand satisfied.
Is Caplin Point Laboratories up to date with its ROC filings?
Annual filings current (balance sheet Mar 2025). Overall compliance score: 50/100 (Moderate).
Is it risky to lend to Caplin Point Laboratories?
Its Credit Risk Score is 85/100 (Low Risk). Banker verdict: Favourable lending indicators.
Disclaimer: This report is generated automatically from MCA filings and public records as available
in our system at the time of the last update. Scores, bands and verdicts are rule-based derived indicators of the
underlying data - they are opinions generated by an algorithm, not statements of fact about the company, and are
not credit ratings (within the meaning of SEBI regulations), audits, or investment, legal or financial advice.
Verify from official sources and consult a qualified professional before any business, lending or investment decision.
If you represent this company and believe any information is inaccurate or outdated,
report it here and we will review promptly.
